Phase 1 Trial of Osimertinib With Stereotactic Radiosurgery (SRS) in Patients With Brain Metastases From EGFR Positive Non-Small-Cell Lung Cancer (NSCLC)
Phase of Trial: Phase I
Latest Information Update: 06 Feb 2019
Price : $35 *
At a glance
- Drugs Osimertinib (Primary)
- Indications Brain metastases; Non-small cell lung cancer
- Focus Adverse reactions
- 29 Jan 2019 Status changed from not yet recruiting to recruiting.
- 12 Nov 2018 Planned initiation date changed from 17 Oct 2018 to 31 Dec 2018.
- 17 Jul 2018 Planned initiation date changed from 23 Jun 2018 to 17 Oct 2018.